Unicycive Therapeutics (UNCY) has regained compliance with Nasdaq continued listing standard for minimum share price. On July 7, the company received confirmation from Nasdaq that as of July 3, the company’s common stock has maintained an average closing share price of at least $1.00 immediately following the company’s 1:10 reverse stock split effective on June 20. The company’s shares are no longer considered to be below the minimum bid price requirement and Nasdaq now considers this matter closed.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UNCY:
- Unicycive Therapeutics approval delay ‘not a surprise,’ says Noble Capital
- Unicycive Receives FDA CRL for New Drug Application
- H.C. Wainwright keeps Buy on Unicycive Therapeutics , says CRL ‘anticipated’
- Buy Rating for Unicycive Therapeutics Amid Regulatory and Financial Optimism
- Unicycive receives CRL for oxylanthanum carbonate NDA for hyperphosphatemia